135 related articles for article (PubMed ID: 7709119)
21. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
23. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
24. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
25. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer adjuvant endocrine therapy.
Cigler T; Goss PE
Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
[TBL] [Abstract][Full Text] [Related]
27. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
28. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
[TBL] [Abstract][Full Text] [Related]
29. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
30. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
31. [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
Roy JA; Piccart MJ
Rev Med Brux; 1995; 16(4):242-4. PubMed ID: 7481234
[TBL] [Abstract][Full Text] [Related]
32. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
Sano M; Makino H
Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
[No Abstract] [Full Text] [Related]
33. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
34. [What is the benefit of adjuvant therapy in breast cancer?].
Sauer H
Fortschr Med; 1992 Nov; 110(30):16-8, 20. PubMed ID: 1468737
[No Abstract] [Full Text] [Related]
35. Pharmacologic manipulation of steroid hormones. Adjunctive therapies in cancer of the breast.
Manni A
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):825-44. PubMed ID: 1778179
[TBL] [Abstract][Full Text] [Related]
36. [Endocrine therapy in breast carcinoma].
Dogliotti L; Maschietto M; Ortega C
Minerva Chir; 1988 Sep; 43(18 Suppl):63-6. PubMed ID: 3067123
[No Abstract] [Full Text] [Related]
37. Hormone therapy in breast cancer.
Kahán Z
Ther Hung; 1992; 40(4):154-62. PubMed ID: 1345021
[TBL] [Abstract][Full Text] [Related]
38. [Systemic adjuvant therapy in patients with operable breast cancer].
Tashiro H; Nomura Y; Hisamatsu K
Rinsho Hoshasen; 1989 Apr; 34(4):443-7. PubMed ID: 2501544
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of cancer of the breast in the metastatic phase].
Clavel M
Pathol Biol (Paris); 1989 Feb; 37(2):137-9. PubMed ID: 2652064
[No Abstract] [Full Text] [Related]
40. [Adjuvant treatment of breast cancer].
Goldhirsch A; Castiglione M
Gynakol Rundsch; 1988; 28 Suppl 1():65-75. PubMed ID: 3042536
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]